HIV infection: epidemiology, pathogenesis, treatment, and prevention

G Maartens, C Celum, SR Lewin - The Lancet, 2014 - thelancet.com
HIV prevalence is increasing worldwide because people on antiretroviral therapy are living
longer, although new infections decreased from 3· 3 million in 2002, to 2· 3 million in 2012 …

Towards an HIV cure: a global scientific strategy

Nature reviews Immunology, 2012 - nature.com
Given the limitations of antiretroviral therapy and recent advances in our understanding of
HIV persistence during effective treatment, there is a growing recognition that a cure for HIV …

[HTML][HTML] Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study

A Sáez-Cirión, C Bacchus, L Hocqueloux… - PLoS …, 2013 - journals.plos.org
Combination antiretroviral therapy (cART) reduces HIV-associated morbidities and
mortalities but cannot cure the infection. Given the difficulty of eradicating HIV-1, a functional …

[HTML][HTML] Modeling the within-host dynamics of HIV infection

AS Perelson, RM Ribeiro - BMC biology, 2013 - Springer
The new field of viral dynamics, based on within-host modeling of viral infections, began with
models of human immunodeficiency virus (HIV), but now includes many viral infections …

Total HIV-1 DNA, a marker of viral reservoir dynamics with clinical implications

V Avettand-Fènoël, L Hocqueloux… - Clinical microbiology …, 2016 - Am Soc Microbiol
SUMMARY HIV-1 DNA persists in infected cells despite combined antiretroviral therapy
(cART), forming viral reservoirs. Recent trials of strategies targeting latent HIV reservoirs …

Cross-clade ultrasensitive PCR-based assays to measure HIV persistence in large-cohort studies

C Vandergeeten, R Fromentin, E Merlini… - Journal of …, 2014 - Am Soc Microbiol
ABSTRACT A small pool of infected cells persists in HIV-infected individuals receiving
antiretroviral therapy (ART). Here, we developed ultrasensitive assays to precisely measure …

Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts

L Hocqueloux, V Avettand-Fenoël… - Journal of …, 2013 - academic.oup.com
Objectives To characterize viro-immunological outcomes following long-term combined
antiretroviral therapy (cART) initiated during primary HIV infection (PHI) or chronic HIV …

[HTML][HTML] HIV-1 transcription and latency: an update

C Van Lint, S Bouchat, A Marcello - Retrovirology, 2013 - Springer
Combination antiretroviral therapy, despite being potent and life-prolonging, is not curative
and does not eradicate HIV-1 infection since interruption of treatment inevitably results in a …

Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation

TA Rasmussen, OS Søgaard, C Brinkmann… - Human vaccines & …, 2013 - Taylor & Francis
Objective: We aimed to compare the potential for inducing HIV production and the effect on T-
cell activation of potent HDAC inhibitors undergoing clinical investigation. Design: In vitro …

[HTML][HTML] Comparison of droplet digital PCR and seminested real-time PCR for quantification of cell-associated HIV-1 RNA

M Kiselinova, AO Pasternak, W De Spiegelaere… - PloS one, 2014 - journals.plos.org
Cell-associated (CA) HIV-1 RNA is considered a potential marker for assessment of viral
reservoir dynamics and antiretroviral therapy (ART) response in HIV-infected patients …